Details of the Drug

General Information of Drug (ID: DMCL2OK)

• Drug Name: Disulfiram
• Synonyms: Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)

Indication

Disease Entry	ICD 11	Status	REF
Alcohol dependence	6C40.2	Approved	[1], [2]

• Therapeutic Class: Alcohol Deterrents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 296.5
  Topological Polar Surface Area (xlogp); 3.9
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
  Bioavailability: 80% of drug becomes completely available to its intended biological destination(s) [4]
  Elimination: 0% of drug is excreted from urine in the unchanged form [3]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 24.0873 micromolar/kg/day [5]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.2 mg/mL [3]
• Chemical Identifiers:
  Formula: C10H20N2S4
  IUPAC Name: diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate
  Canonical SMILES: CCN(CC)C(=S)SSC(=S)N(CC)CC
  InChI: InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
  InChIKey: AUZONCFQVSMFAP-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3117
  ChEBI ID: CHEBI:4659
  CAS Number: 97-77-8
  DrugBank ID: DB00822
  TTD ID: D0X5SD
  VARIDT ID: DR00310
  INTEDE ID: DR0519
  ACDINA ID: D00206

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fatty aldehyde dehydrogenase (ALDH3A2)	TTB6UM0	AL3A2_HUMAN	Inhibitor	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[8]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[9]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Disulfiram (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Disulfiram and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[42]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Disulfiram and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[43]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Disulfiram caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[44]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Disulfiram and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[45]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Disulfiram caused by Oxtriphylline mediated inhibition of CYP450 enzyme.	Cough [MD12]	[44]
Sertraline	DM0FB1J	Major	Decreased metabolism of Disulfiram caused by Sertraline mediated inhibition of non-CYP450 enzyme.	Depression [6A70-6A7Z]	[46]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Disulfiram caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[47]
Isoniazid	DM5JVS3	Moderate	Additive dopaminergic effects by the combination of Disulfiram and Isoniazid.	HIV-infected patients with tuberculosis [1B10-1B14]	[48]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Disulfiram and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[49]
Tipranavir	DM8HJX6	Major	Decreased metabolism of Disulfiram caused by Tipranavir mediated inhibition of non-CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Disulfiram and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Abacavir	DMMN36E	Minor	Increased plasma concentrations of Disulfiram and Abacavir due to competitive inhibition of the same metabolic pathway.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Disulfiram and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[53]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Disulfiram and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[54]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Disulfiram and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[55]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Disulfiram caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[56]
Paraldehyde	DMOC1BX	Major	Decreased metabolism of Disulfiram caused by Paraldehyde mediated inhibition of non-CYP450 enzyme.	Insomnia [7A00-7A0Z]	[42]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Disulfiram and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[57]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Disulfiram and Idelalisib.	Mature B-cell leukaemia [2A82]	[58]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Disulfiram caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[42]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Disulfiram and Thalidomide.	Multiple myeloma [2A83]	[51]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Disulfiram and Leflunomide.	Rheumatoid arthritis [FA20]	[54]
Vardenafil	DMTBGW8	Moderate	Decreased metabolism of Disulfiram caused by Vardenafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[59]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Disulfiram 250 mg tablet	250 mg	Oral Tablet	Oral
Disulfiram 500 mg tablet	500 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7168).
• [2] Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep. 2006 Oct;8(5):383-8.
• [3] BDDCS applied to over 900 drugs
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76.
• [7] Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014 Mar-Apr;23(2):137-44.
• [8] Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J Pharmacol Exp Ther. 1999 Oct;291(1):213-9.
• [9] Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res. 1998 Sep;22(6):1212-9.
• [10] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [11] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [12] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [13] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [14] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [15] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [16] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [17] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [18] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [19] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [20] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [21] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [22] Drug Interactions Flockhart Table
• [23] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [24] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [25] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [26] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [27] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [28] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [29] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [30] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [31] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [32] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [33] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [34] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [35] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [36] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [37] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
• [38] Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline. Epilepsy Res. 2006 June; 69(3): 273-294.
• [39] Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast... J Med Chem. 2010 Apr 8;53(7):2757-65.
• [40] Elgonica-Dimers A and B, Two Potent Alcohol Metabolism Inhibitory Constituents of Aloe arborescens J. Nat. Prod. 60(11):1180-1182 (1997).
• [41] Aldehyde dehydrogenase inhibitors: alpha,beta-acetylenic N-substituted aminothiolesters are reversible growth inhibitors of normal epithelial but i... Eur J Med Chem. 2008 May;43(5):906-16.
• [42] Cerner Multum, Inc. "Australian Product Information.".
• [43] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [44] Loi CM, Day JD, Jue SG, et al "Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics." Clin Pharmacol Ther 45 (1989): 476-86. [PMID: 2721103]
• [45] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [46] Product Information. Antabuse (disulfiram). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [47] Brown CG, Kaminsky MJ, Feroli ER, Gurley HT "Delirium with phenytoin and disulfiram administration." Ann Emerg Med 12 (1983): 310-3. [PMID: 6625283]
• [48] Whittington HG, Grey L "Possible interaction between disulfiram and isoniazid." Am J Psychiatry 125 (1969): 1725-9. [PMID: 5770196]
• [49] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
• [50] Elenbaas RM "Drug therapy reviews: management of the disulfiram-alcohol reaction." Am J Hosp Pharm 34 (1977): 827-31. [PMID: 331944]
• [51] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
• [52] Product Information. Ziagen (abacavir). Glaxo Wellcome, Research Triangle Pk, NC.
• [53] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [54] Canadian Pharmacists Association.
• [55] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [56] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [57] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [58] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [59] Product Information. Levitra (vardenafil). Bayer, West Haven, CT.